The PoNS Device, designed for multiple sclerosis patients, aids in gait improvement through a non-invasive neuromodulation approach. Reimbursement approval from major payers signals growing ...

The PoNS device is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...

Helius Medical (HSDT) Technologies announced its first reimbursement payment from a major healthcare provider, Anthem Blue Cross Blue Shield, for its Portable Neuromodulation Stimulator, PoNS ...

The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an ...

The PoNS device is approved in Canada where it is used, in conjunction with physical therapy, for the short-term treatment of gait deficit due to mild and moderate symptoms from multiple sclerosis ...

NEWTOWN, Pa. - Helius Medical Technologies, Inc. (NASDAQ:HSDT), a medical device company with a market capitalization of $0.45 million, announced Wednesday that Aetna Healthcare has authorized a claim ...

The PoNS device, being developed initially as a treatment for balance disorders in traumatic brain injury patients, works by delivering neurostimulation through the tongue — which contains ...

Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ TrainingNEWTOWN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) will showcase ...